- Home
- BXC vs CSTL Comparison
BXC vs CSTL Comparison
Compare BXC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- CSTL
- Stock Information
- Founded
- BXC 2004
- CSTL 2007
- Country
- BXC United States
- CSTL United States
- Employees
- BXC N/A
- CSTL N/A
- Industry
- BXC Wholesale Distributors
- CSTL Medical Specialities
- Sector
- BXC Consumer Discretionary
- CSTL Health Care
- Exchange
- BXC Nasdaq
- CSTL Nasdaq
- Market Cap
- BXC 663.8M
- CSTL 568.2M
- IPO Year
- BXC 2004
- CSTL 2019
- Fundamental
- Price
- BXC $71.94
- CSTL $21.51
- Analyst Decision
- BXC Strong Buy
- CSTL Strong Buy
- Analyst Count
- BXC 5
- CSTL 6
- Target Price
- BXC $125.20
- CSTL $40.00
- AVG Volume (30 Days)
- BXC 107.0K
- CSTL 330.2K
- Earning Date
- BXC 04-29-2025
- CSTL 05-05-2025
- Dividend Yield
- BXC N/A
- CSTL N/A
- EPS Growth
- BXC 14.84
- CSTL N/A
- EPS
- BXC 6.19
- CSTL 0.62
- Revenue
- BXC $2,952,532,000.00
- CSTL $332,069,000.00
- Revenue This Year
- BXC $4.52
- CSTL N/A
- Revenue Next Year
- BXC $5.77
- CSTL $3.34
- P/E Ratio
- BXC $11.62
- CSTL $34.69
- Revenue Growth
- BXC N/A
- CSTL 51.09
- 52 Week Low
- BXC $67.42
- CSTL $16.97
- 52 Week High
- BXC $134.79
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- BXC 41.60
- CSTL 56.26
- Support Level
- BXC $68.70
- CSTL $18.03
- Resistance Level
- BXC $72.91
- CSTL $20.77
- Average True Range (ATR)
- BXC 4.21
- CSTL 1.27
- MACD
- BXC 0.19
- CSTL 0.41
- Stochastic Oscillator
- BXC 42.09
- CSTL 93.06
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.